期刊文献+

外科治疗原发性甲状腺机能亢进并突眼征52例临床分析

Clinical analysis of 52 cases of primary hyperthyroidism combined with exophthalmos by surgical treatment
下载PDF
导出
摘要 目的分析外科治疗对原发性甲状腺功能亢进并突眼征患者突眼度的影响。方法对52例原发性甲状腺功能亢进并突眼征患者行双侧甲状腺次全切除术治疗,在手术治疗前及治疗后1 d、1个月、3个月、6个月检测患者甲功及突眼度。结果 52例患者手术后甲亢病情治愈,术后1、3、6个月突眼与术前1 d对比突眼度差异有统计学意义(P<0.05),术后患者突眼度逐渐减少,眼征好转。结论原发性甲状腺机能亢进并突眼征患者可行手术治疗,原发性甲状腺功能亢进并轻中度突眼患者外科治疗后突眼度可缩小,眼征改善。 Objective To analyze the impact of surgical treatment on patients with primary hypothyroidism combined with exophthalmos. Methods Fitby-two patients of primary hypothyroidism combined with exophthalmos were treated with bilateral subtotal thyroidectomy surgery. The thyroid function and exophthalmos degree were detect- ed 1 day before operation and 1, 3, 6 months after operation. Results Primary hypothyroidism was cured in the 52 patients. There was statistically significant differences in exophthalmos degree 1 day before operation and 1, 3, 6 months after operation (P〈0.05). The exophthalmos degree gradually reduced, and eye symptoms were improved. Conclusion Surgical treatment is feasible for patients of primary hyperthyroidism combined with exophthalmos. The exophthalmos degree of primary hyperthyroidism and mild-to-moderate exophthalmos can be reduced after surgi- cal treatment, and the eye symptoms can be improved.
出处 《海南医学》 CAS 2013年第20期2996-2997,共2页 Hainan Medical Journal
基金 2011年度佛山市卫生局医学科研立项(编号:2011094)
关键词 外科治疗 原发性甲状腺功能亢进 突眼度 Surgical treaUnent Primary hyperthyroidism Exophthalmos degree
  • 相关文献

参考文献6

二级参考文献29

  • 1孙治华,姚斌,廖瑛,翁建平.甲状腺刺激抗体与Graves眼病临床特点的关系[J].中华内分泌代谢杂志,2006,22(5):457-458. 被引量:11
  • 2Perros P, Baldeschi L, Boboridis K, et al. A questionnaire survey on the management of Graves'orbitopathy in Europe [ J ]. Eur J Endocrinol,2006,155 (2) :207 - 211.
  • 3Matejka G, Verges B, Vaillant G, et al. Intravenous methylpred- nisolone pulse therapy in the treatment of Graves'ophthalmopathy [J]. Horm Metab Res,1998,30(2) :93 -98.
  • 4Kahaly GJ, Pitz S, Hommel G, et al. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves'orbitopathy[J]. J Clin Endocfinol Metab,2005,90(9) :5234 -5240.
  • 5Law KM, Woo GC. Thyroid disease induced diplopia [ J ]. Clin Exp Optom,2009,92( 1 ) :30 - 33.
  • 6Ronchi CL,Boschetti M,Degli UEC,et al. Efficacy of a slow -release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR) :an open, multicentre longitudinal study [ J ]. Clin Endocrinol (Oxf) ,2007,67(4) :512 -519.
  • 7Bradley EA, Gower EW, Bradley D J, et al. Orbital radiation for graves ophthalmopathy : a report by the American Academy of Ophthalmology [ J ]. Ophthalmology,2008,115 (2) :398 - 409.
  • 8Wei RL, Cheng JW, Cai JP. The use of orbital radiotherapy for Graves" ophthalmopathy: quantitative review of the evidence [ J ]. Ophthalmologiea ,2008,222 ( 1 ) :27 - 31.
  • 9Chang S, Perry JD, Kosmorsky GS, et al. Rapamycin for treatment of refractory dysthyroid compressive optic neuropathy [ J ]. Ophthal Plast Reconstr Surg,2007,23 ( 3 ) :225 - 226.
  • 10Bartahna L,Pinchera A,Marcocci C.Management of Graves'ophthalmopathy:reality and perspectives[J].Endocr Rev,2000,21(2):168-199.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部